Your immune system has a memory. It can recognize certain microbes it has already encountered and respond quickly to their return. Could this memory also be strengthened against cancer?
A new study combining an anticancer drug with an experimental antibody has demonstrated this protection in mice. After their tumors disappeared, the animals resisted another injection of the same cancer cells a few weeks later, without further treatment.
Researchers at Regeneron Pharmaceuticals, an American biotechnology company, wanted to boost cancer treatment by helping the immune system join the attack.
Part of the first combination was an established cancer drug. Sold under the name Enhertu, trastuzumab deruxtecan consists of an antibody carrying a cell-killing payload. The antibody binds to a growth-related protein called HER2, helping to deliver this payload to cells carrying the protein.
Enhertu is already used for certain breast, stomach and other cancers, depending on the characteristics of the tumor and previous treatments. The experimental antibody added in this study had a different role: supporting immune cells that attack tumors.
These defenders include T cells, which can recognize and kill cancer cells. An effective response generally requires both recognition of a target and an additional activating signal.
The experimental antibody binds to two different targets. One part attaches to a protein on tumor cells, while the other engages a T-cell activating protein called CD28. This dual-target design makes it a “bispecific” antibody.
The researchers tested the combinations in mice carrying modified mammary or colorectal tumors. Animals expressed human CD28 and modified versions of selected drug targets. For HER2 and another growth-related protein, EGFR, the exposed external parts were human, while the internal and membrane parts remained mouse. Tumor cells were also engineered to display relevant targets.
In initial breast cancer testing, the cancer drug alone produced complete tumor responses in fewer than half of the mice, even at the highest dose tested. Combined with the experimental antibody, it eliminated tumors in all nine mice receiving both treatments.
The researchers then wondered whether the protection would last. After the mice remained tumor-free for at least four weeks, the team reinjected the same breast cancer cells. The animals rejected them without further treatment.
Another comparison revealed what their immune systems remembered. A different colorectal tumor developed in the previously treated mice, even though its cells also carried HER2. This suggests that protection recognizes other features of the cancer of origin beyond the shared protein.
Removing a group of cancer-fighting T cells, known as CD8 T cells, completely abolished the benefits of the original combination, demonstrating that these cells were critical to its success.
The team also tested an experimental antibody targeting EGFR, already in early stage (phase 1/2) human trials. Combined with Enhertu, it caused tumor rejection in approximately 75% of mice in a breast tumor model more resistant to Enhertu alone.
The same antibody also worked with the chemotherapy drug fluorouracil, or 5-FU, already used for colorectal and other cancers. Together, the treatments slowed the growth of colorectal tumors while either treatment alone had little effect.
This combination relied on both CD8 T cells and another anti-cancer population, called natural killer or NK cells. The treatment retained some activity when either population was absent. Its benefit completely disappeared when both were missing.
To study the immune response against cancer, researchers looked at cells inside tumors and analyzed gene activity. The combinations increased active T cells while preserving less mature cells that could support future responses.
They also increased the diversity of receptors used by T cells to recognize their targets, potentially helping them recognize more characteristics of cancer.
Enhertu increased and activated dendritic cells, which show pieces of tumor material to T cells. In mice genetically modified to lack a particular group of these cells, the Enhertu-antibody combination completely lost its effectiveness.
The chemotherapy drug worked differently. This caused other immune cells to support an attack and reduced the populations that suppress it.
Some combinations remained effective with lower drug doses or less frequent chemotherapy, potentially reducing treatment burden if confirmed in patients.
Mouse models cannot reproduce the full range of side effects people can experience, including damage to the lungs, intestines, heart and skin. Efficacy and safety in humans require further evaluation.
Regeneron funded the research. All authors are current or former employees, and provisional patent applications related to the work have been filed.
The research was published in Natural communications.
This article was fact-checked by Fiona MacDonald and edited by Fiona MacDonald. Although we are proud of our process, we are only human. If you spot an error, please let us know.
Gn tech
